Selected article for: "acute ards respiratory distress syndrome and lung cytokine storm"
Author: Baindara, Piyush; Agrawal, Sonali; Mandal, Santi M.
Title: Host-directed therapies: a potential solution to combat COVID-19
  • Cord-id: u3o4xu29
  • Document date: 2020_8_12
    • ID: u3o4xu29
    Snippet: Coronavirus disease 2019 (COVID-19) characterized by immuno-pathological host responses including pneumonia, lymphopenia, and cytokine storm that leads to severe lung inflammation, developed in acute respiratory distress syndrome (ARDS). In the absence of an effective vaccine or any definitive cure, the use of host-directed therapies is an effective alternative and demanding treatment option in the current pandemic outbreak of COVID-19.
    Document: Coronavirus disease 2019 (COVID-19) characterized by immuno-pathological host responses including pneumonia, lymphopenia, and cytokine storm that leads to severe lung inflammation, developed in acute respiratory distress syndrome (ARDS). In the absence of an effective vaccine or any definitive cure, the use of host-directed therapies is an effective alternative and demanding treatment option in the current pandemic outbreak of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and low activity: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and lung alveolar space: 1
    • acute ards respiratory distress syndrome and lung pathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • adalimumab infliximab and low activity: 1, 2
    • lmwh weight heparin and low activity: 1, 2
    • lmwh weight heparin and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25